<SEC-DOCUMENT>0001213900-19-022361.txt : 20191107
<SEC-HEADER>0001213900-19-022361.hdr.sgml : 20191107
<ACCEPTANCE-DATETIME>20191107161544
ACCESSION NUMBER:		0001213900-19-022361
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20191105
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191107
DATE AS OF CHANGE:		20191107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptimizeRx Corp
		CENTRAL INDEX KEY:			0001448431
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				261265381
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38543
		FILM NUMBER:		191200524

	BUSINESS ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
		BUSINESS PHONE:		248-651-6558

	MAIL ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k110519_optimizerxcorp.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WASHINGTON,
D.C. 20549<BR></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 20%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 13 OR 15(d) OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SECURITIES EXCHANGE ACT OF 1934<BR>
<BR>
</B>Date of Report (Date of earliest event reported): November 5, 2019<BR>
<BR>
<U>OptimizeRx Corporation</U><BR>
(Exact name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; text-align: center; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 2%; text-align: center; padding: 0 0 1.5pt; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: center; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38543</FONT></TD>
    <TD STYLE="width: 2%; text-align: center; padding: 0 0 1.5pt; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: center; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26-1265381</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction<BR>
of incorporation)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File Number)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer<BR>
Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; text-align: center; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">400
    Water Street, Suite 200, Rochester, MI</FONT></TD>
    <TD STYLE="width: 2%; text-align: center; padding: 0 0 1.5pt; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; text-align: center; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48307</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
telephone number, including area code: <U>248.651.6568</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="width: 96%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    symbol</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 38%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPRX</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
    Capital Markets</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8 &ndash; Other Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8.01 Other Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 5, 2019, the Company held a conference call to discuss the Company&rsquo;s 2019 third quarter earnings and other matters
of business, a transcript of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for
purposes of Section 18 of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange
Act, except as expressly set forth by specific reference in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9 &ndash; Financial Statements and Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01 Financial Statements and Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 7%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 93%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="f8k110519ex99-1_optimizerx.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conference call transcript dated November 5, 2019</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OptimizeRx
Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 40%; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Doug Baker</FONT></TD>
    <TD STYLE="width: 60%; padding: 0 0 1.5pt; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doug
    Baker<BR>
    Chief Financial Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 7, 2019</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k110519ex99-1_optimizerx.htm
<DESCRIPTION>CONFERENCE CALL TRANSCRIPT DATED NOVEMBER 5, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="width: 554px; height: 401px"></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: left; margin-bottom: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>C O R P O R A T E P A R T I C I P A
N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo, </B><I>Chief Executive
Officer &amp; Director</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker, </B><I>Chief Financial
Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro, </B><I>Chief Commercial
Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Miriam Paramore, </B><I>President</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>C O N F E R E N C E C A L L P A R T
I C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew D&rsquo;Silva, </B><I>B. Riley FBR,
Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Richard Baldry, </B><I>ROTH Capital</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ryan Daniels, </B><I>William Blair</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Bruce Goldfarb, </B><I>Lake Street Capital
Markets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Josh Goldberg, </B><I>G2</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ron Chez, </B><I>Private Investor</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>P R E S E N T A T I O N</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good afternoon and thank you for joining
us today to discuss OptimizeRx Corporation third quarter ended September 30, 2019. With us today is the Company&rsquo;s Chief Executive
Officer, William Febbo and the Company&rsquo;s President, Miriam Paramore. They are joined by the Company&rsquo;s Chief Financial Officer,
Doug Baker; and Chief Commercial Officer, Stephen Silvestro. Following their remarks today, we&rsquo;ll open the call to questions. Then,
before we conclude today&rsquo;s call, I&rsquo;ll provide some important cautions regarding the forward-looking statements made by the Management
during the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;d like to remind everyone that today&rsquo;s
call is being recorded and will be made available for telephone replay via instructions in today&rsquo;s press release in the Investors
section of the Company&rsquo;s website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now, I&rsquo;d like to turn the call over to
OptimizeRx&rsquo;s CEO William Febbo. Please go ahead, sir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you, and good afternoon everyone.
Thanks for joining us today. During the third quarter, we made broad advances with our digital health platform scaling it beyond
pharma with the relevant set of solutions designed to assure greater adherence, affordability, and patient engagement. As you saw
in the press release we issued earlier today, we experienced a rare set back in year-over-year revenue growth. This was primarily
due to the confluence of two unusual events involving three of our larger clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">First, one of our clients decided to stop
supporting one of the brands about 12 months prior to their loss of exclusivity coming up in 2020, which in our experience was
earlier than usual. The loss of this brand represented about $2 million in annual revenue or less than 10% of our revenue for the
year. However, we believe we have a solid relationship with this client and have visibility in the future business with new brands
they will be introducing. We also have more than 20 other brands which have increased their year-over-year budget, and are looking
to grow considerably into 2020. Steve will talk to this more later in the call. I should also mention that we have been diversifying
our revenue stream over the course of the last year both internally and through acquisition, and we expect this to lessen the impact
of any similar future event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Secondly, the merger of two of our larger
clients which is now complete, pushed out about $3 million in revenue from the second half of &lsquo;19 into 2020. There were initial
indications this would not happen, but it is now clear the revenue will go into next year. While in the past, we have successfully
navigated similar risk factors, the timing of this one was unfortunately out of our control. The good news is this relationship
remains strong and we hope to benefit from the synergies of a newly merged company reaching larger and multiple budgets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aside from these two events, the prospects
of our business continue to be very positive. We have a strong understanding what it looks like going forward and what is in line
with market expectations and our messaging today. We expect our new expanded commercial team to have a positive impact on Q4 and
an even greater impact on 2020. In fact, we anticipate very strong growth in Q4 as compared to last year and are seeing traditional
seasonal upselling opportunities like we have in the past. Along this line, we have decided to start sharing some of the details
of our sales pipeline going into each year end session. We are planning to do this in the third quarter earnings call, which will
help set expectations for the following year. Steve will provide the numbers and more of the details around the pipeline later
in the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Importantly, our pipeline is reflecting
our gradual transition from primarily a pay for distribution model to one that is more impact driven, that is, one defined by the
value we create for our client such as increased revenue and efficiency of disseminating critical information. While this transition
will not happen over night, we expect it to be largely completed by this time next year. We expect a key benefit of this to be
more predictable recurring revenue stream with this being generated by enterprise engagements with our top 20 clients. This will
involve a true SaaS revenue component provided by our recent acquisition of RMDY Health as well as partnership revenue, which is
more predictable. We are also seeing greater diversity in our revenue as a result of initiatives we launched last year created
and driven by the industry thought leaders we&rsquo;re fortunate to have on our team. These initiatives have been focused on delivering
multiple solutions at the point of care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These solutions have been designed to address
the emerging trends in our industry and especially to further close the communication gap between pharma, physicians, and patients.
Closing this gap has become increasingly important especially with the wave of new speciality medications coming onto the market
as well as the increasing value being placed on the patient journey as it relates to medication adherence. The recognition of these
trends has driven our efforts to broaden our reach from physicians to interacting directly with patients. Given how adherence has
become one of the largest issues facing our clients today, our greater connection to patients has taken us beyond being simply
a brand or financial message provider to now an essential partner for our clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another important point in our assessment
of the market is that we began to see maturing of our financial messaging products earlier this year. While we still anticipate
growth with these messaging solutions, we also expect a maturation, and competitive factors will become increasingly reflected
in the pricing. Good news is that we have always been among the first to innovate and get ahead of the trends. We have built the
suite of solutions for pharma that are highly relevant with financial messaging no longer representing the majority of our revenue.
Our recent acquisitions have also enabled multiple new channels, partners, and client segments, all of which will help us continue
to grow and diversify our revenue stream.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our recent acquisition of RMDY Health has
increased our total addressable market several folds while further diversifying our client base to include payers, medtech, and
wellness companies. RMDY also brought to us a SaaS based pricing model that provides a recurring revenue stream with high gross
margins and greater predictability. We firmly expect at least 100% growth from this over the next 12 months. Miriam and Steve will
talk more to this shortly. But to be sure we are still very committed to the messaging within the EHR channel and point of care
communications with this demonstrated by our recent new crop announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now, I&rsquo;d like to hand the call over to
Doug to provide the financial details for the quarter. Steve will then give us a view of our pipeline and client segments, followed
by Miriam who will discuss our strategic shift where we are leveraging our technology and partnerships to drive growth. Afterward,
I&rsquo;ll return with a few anecdotes about our business, clients, and team and then open up the call to Q&amp;A. Doug?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Will, and good afternoon everyone.
Earlier today, we issued a press release with results of our third quarter, which ended September 30, 2019. A copy is available
for viewing and may be downloaded from the Investor Relations section of our website. We also filed our 10-Q this afternoon as
well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the second quarter of 2019, our total
revenue decreased about $400,000 to $5 million primarily due to the client events Will discussed. Despite the decrease in revenue,
we maintained a gross margin of 60.4%, which was up from 58.1% in the year-ago quarter. Then, improvement was due to a favorable
shift in product mix. We expected to continue to maintain gross margins of at least 60% on a quarterly basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operating expenses totaled $5 million,
up from $2.9 million in the same year-ago quarter. This increase was due to additional expenses related to our growth initiatives,
including our acquisition of CareSpeak Communications in October 2018 and other new hires in the last year. Approximately $1.1
million of expenses related to our recent acquisition of RMDY Health and research related to potential new product offerings is
also included in the quarter. There will be similar expenses in the fourth quarter, but these type of expenses are not expected
to occur on an ongoing basis. We continued to watch our expenses closely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the third quarter, our bottom line
on a GAAP basis was a net loss of $1.6 million or $0.11 per share. This compares to net income of $245,000 or $0.02 per share in
the third quarter of 2018. While we expect to remain cash flow positive and return to GAAP profitability on a quarterly basis,
one time expenses related to investments in growth initiatives or non cash charges could result in GAAP loss in any given quarter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Starting in the fourth quarter of 2018,
we began reporting two non-GAAP financial measures, non-GAAP net income or loss and non-GAAP earnings per share or EPS. We believe
the use of these measures can be helpful in assessing the Company&rsquo;s financial performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the third quarter of 2019, our non-GAAP
net loss was $0.05 per share. This compares to a non-GAAP net income of $0.08 per diluted share in the same year-ago quarter. For
additional information about our use of these non-GAAP measures and their reconciliation to GAAP, please see the related section
in today&rsquo;s press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Turning to our balance sheet, cash and
cash equivalents totaled $29.8 million at September 30, 2019. This compares with $30.5 million at the end of June 2019. The decrease
was due to cash used in operations. We have continued to operate debt-free. In fact, we only used $160,000 in cash for operations
for the first nine months of the year. This resulted from increased working capital needs to support the higher revenue levels.
We expect our net income or loss adjusted for non cash expenses to remain positive on a quarterly basis for the foreseeable future.
We do not anticipate needing to raise any additional capital in the short or long term for operating purposes or to fund our growth
plans. We are focused on growing our revenue channel and partner network. However, as a company in a market that is active with
M&amp;A activity, we may have opportunities such as for acquisitions or strategic partner relationships that may require additional
capital. We will assess these opportunities as they arise and always with a view towards maximizing shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This wraps up our financial results, so
now I&rsquo;d like to turn the call over to Steve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestror:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Doug. Now with what we view as
a temporary revenue shortfall behind us, I hope to convey our strong optimism around our future, both immediate and long term.
Looking first at the numbers, our aggregate pipeline, which is comprised of outstanding RFPs we have submitted, is showing a 50%
increase over last year and sits today at around $70 million. For such RFPs, we have historically achieved a 35% to 50% close rate.
In addition to the significant pipeline growth, we have five enterprise deals totaling $30 million, which we are currently reviewing
with our clients. These deals while in early stages address the need for holistic solution set for improving adherence, which we
are all well positioned to deliver on. We believe there will be more to come as we progress these initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial organization has really
come together nicely in the past couple of months such that we are able to address the increasing demands of our core customers
within the pharma industry and service our new client segments of payers, medtech, and medical associations. Our team in client
expansion aligns with our passion for improving adherence and ultimately better outcomes for patients. We are also witnessing an
accelerated migration to digital solutions by pharma with an augmented focus on patient experience specifically. Manufacturers
are anxious to link key puzzle pieces of the care continuing together to provide added clarity and empower physicians with the
tools they need to help their patients. This move aligns with our unique ability to reach and educate physicians at the point of
care, so they can have more informed conversations with their patients about treatment options. Every patient presents a unique
challenge and OptimizeRx has the tools and solutions to help our pharma customers and the physicians in the network to navigate
these complexities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to more effectively and efficiently
support greater adherence through messaging, we have recently completed the integration of our core set of digital solutions into
a single platform with this including the addition of several new robust capabilities. It now provides pharma manufacturers and
enterprise mobile solution that could improve patient retention, reduce therapy event, and improve overall care outcomes, all in
a harmonious way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our integrated platform approach also allows
us to address the needs of a much larger group of manufacturers and we have identified 29 manufacturers whose specific needs directly
align with our new platform solution. The benefits of this integration have already begun to appear in the growth of our aggregate
pipeline including an increase of our average deal size from $130,000 in 2018 to $300,000 in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our recent acquisition of RMDY Health adding
three new members to our commercial sales team will be focused on the payer market. We welcome Anthem, Mobi and other new clients
and we look forward to growing that segment aggressively over the next two to three years. We are also hiring two more sales professionals
over the next few months who will focus directly on the payer segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given the increasing activity in digital
health management and patient engagement space, we expect to see solid growth in our SaaS based recurring revenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;d now like to turn the time over to Miriam,
our President.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Miriam Paramore:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks Steve. I would like to address three
important topics today. First backing up a little bit, is the strategy that Will talked about before. This drives our product portfolio
and why it matters. Second, a major win we recently had through our new exclusive agreement with NewCrop and the launch of our
Innovation Lab. And lastly how RMDY will help us drive revenue and profitability as a new important segment of our platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regarding strategy first, as our business
strategy growth and changes, so does our portfolio of solutions. Earlier this year, we made a strategic decision to enter the payer
market and the acquisition of RMDY gives us some powerful tools to meet their needs, particularly in the areas of digital care
management and digital member engagement. Steve has already talked about how our portfolio of solutions matches the needs of the
pharma sector. I would like to expand on how a strategically orchestrated portfolio of solutions can meet both pharma and payer
needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRx was built on the value we create
for pharma through our EHR network, the value of aggregation for those in the healthcare ecosystem who want to communicate digitally
with providers at the point of care. We have created a successful business by lighting up this network for use by the pharma sector.
We believe we can do the same with the payer sector. Payers also want to communicate with the point of care to help improve their
relationships with the healthcare providers and to support their members&rsquo; health journeys.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our OPRX EHR network is now only one part
of our unified cloud based platform. Leveraging on the EHR network and the cloud to support both the pharma and payer sectors can
yield tremendous economy of scale. Leveraging our platform across multiple market sectors shows how we are expressing our business
strategy through our product strategy. Our EHR channels continue to grow into trajectories. We continue to add new channel partners
and as they scale we add new providers to our network. At the same time, we find ways to expand upon the number of ways we communicate
with providers within each EHR channel. For example, we currently connect pharma manufacturers to providers in real time at the
point of prescribing. We also provide other clinical content at the same point in the EHR work flow. In addition, we are finding
other valuable ways to communicate in other parts of the work flow. This expanded digital footprint within an EHR channel is a
revenue multiplier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now moving onto channel and our NewCrop
focus specifically. Beyond the value of network expansion and messaging scale, we are introducing innovation value through our
unique relationships with key EHR and e-prescribing channel partners. Last month, we announced a new exclusive agreement with NewCrop,
which has an industry leading e-prescribing platform that is used by more than 65,000 healthcare providers. After several years
of an existing successful partnership with NewCrop, our new agreement gives us exclusive rights to digital messaging of any type
within the NewCrop platform. We expect this access to significantly improve our pharma messaging revenue while creating significant
competitive barriers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have seen tremendous success through
our previous programs with NewCrop. Their point of prescribing access to healthcare providers is a great match for our digital
platform and has allowed us to offer our pharma partners unmatched efficiency in their marketing spends. For NewCrop, our enhanced
partnership means broader distribution of medication specific information delivered conveniently within their healthcare providers&rsquo;
daily work flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Then it goes beyond that, I want to talk
about our Innovation Lab. As exciting as that is, we are even more excited to include NewCrop as our founding partner in the launch
of the OptimizeRx Innovation Lab. The lab will be the perfect incubator for creating and testing point of care solutions for both
pharma and payers. It is unparalleled in the industry, providing a much needed test bed for piloting and measuring new ideas to
improve outcomes for patients and lower stress for providers. We are already working with several pharma brands on pilots that
will utilize the OptimizeRx Innovation Lab and the NewCrop e-prescribing reach. Stay tuned over the next few quarters as we experiment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finally, I would like to talk about how
the RMDY health suite complements our strategic product portfolio. OptimizeRx Management sees that healthcare is ready for digital
solutions across the board and especially in the areas of patient engagement, adherence, and care management. According to a recent
study, the lack of medication adherence cost the U.S. Health System as much as $528 billion in terms of illness and death that
result from poorly followed medication therapy. Patients are at risk of contributing to this public health challenge when they
avoid filling or refilling prescription. There are strategies than can help manage this risk in order to lower care cost and improve
health. We need to address this through an ecosystem wide holistic lens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have invested in RMDY to broaden our
solution set and address this market shift to digital. We now have native SMS text based solutions as well as highly customizable
mobile app solutions. The RMDY acquisition is transformational for us in two ways. Number one, it expands our client base from
one to three segments to include companies like Anthem, Medtronic, the American Heart Association and others. Number two, it is
largely a SaaS model, hence recurring revenue and strong gross margins of 90%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Broadly speaking, RMDY is a digital care
management solution that can be used by any sponsor to help patients or consumers on their health journeys. It comes along side
our previous acquisition of CareSpeak to help us expand on offerings in those areas. We are confident in our ability to drive revenue
growth with these new segments. In fact, inside of one year, we have seen 100% revenue growth and great margin contribution from
the CareSpeak product line with this being driven by the strong industry need for digital solutions that engage patients across
their health journey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now, I&rsquo;d like to turn the call back
over to Will.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Miriam, Doug, and Steve. As we
look ahead, it is clear we are addressing a large market with the significant penetration opportunity and as you heard from Steve
and Miriam, our digital health platform addresses many pain points for all involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to grow our market share, we are
focused intently on expanding revenue by client and reaching new client segments. We are also working to expand our solution set,
EHR network, and strategic partnerships. With our acquisitions of CareSpeak and RMDY, we have expanded our total addressable market
by several folds adding digital care and health management to our solution set.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not only better able to address
our existing HCP messaging market, which is estimated at more than $2.4 billion, but now the patient engagement market, digital
therapeutics and care management. This brings our total addressable market to north of $48 billion. This means we see a lot of
room for growth ahead in this year and beyond, and as we continue to track and retain the most capable team to size this opportunity
and take advantage of it, we are very excited about the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our EHR and e-prescribing platform currently
reaches most of the EHRs that enable messaging within point of care. Our success in acquiring, integrating and expanding into new
EHR ERX platforms continues to grow. We view them as our partners. We deliver needed content to their members and ultimately revenue
to their businesses. We are very proud of our channel network and appreciate everything they do for the healthcare ecosphere. Over
time, they will need to innovate with us and we are proud that NewCrop selected us as their preferred partner as Allscripts or
Veradigm did many years ago.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue to enjoy tremendous market
opportunity being perfectly positioned between all the stakeholders of pharma, physicians, patients and now payers. Our platform
now supports multiple revenue streams while delivering greater affordability, adherence and care management. We plan to remain
focused on driving revenue growth from our core solutions, expanding our network and seeking solid M&amp;A and partnership opportunities.
We expect this to drive continued adoption of our health platform across our entire client base.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we drive the growth of our pharmaceutical
products and distribution network, we can expect that all our messaging solutions will continue to grow along with our patient
engagement activities. All this should drive another year of fantastic growth when we round out 2019. I have to say seeing now
what is happening with our new expanded commercial team in terms of building the pipeline for 2020, the new solutions we will announce
in the coming months and some potential M&amp;A opportunities, I am more enthusiastic than ever about our prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To those shareholders who have stayed with
us over the last few years and helped us greatly as we have grown from being simply a collection of products into a fully fledged
diverse growth company, we deeply value your participation and support. I hope we&rsquo;ve earned your trust and we will continue
to innovate and evolve with the market and continue to build a meaningful, highly successful and profitable business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For our new investors, I imagine we are
still in the trust, but verify stage; but for all, we promise as a team that we will remain steadfastly focused on building share
holder value as we strive to support our clients and help them improve patient care. Now with that, we should get to the more important
part of Q&amp;A. I will hand it over to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you. At this time, if you do have
a question, please signal by pressing star, one. Again, that will be star, one for questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We&rsquo;ll hear first today from Andrew D&rsquo;Silva
with B.Riley FBR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew D&rsquo;Silva:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good afternoon, thanks for taking my questions,
Doug, real quick just, from you. If you could just explain the $280,000 benefit related to the earnouts from CareSpeak, any color
on why there was a claw back there. And then while you are pulling that itself, if you could provide a little color on that left
earlier, where it states it relates to the brand, like, what is the rationale that they gave you, just too much confidence and
air space, or if they do not prefer to just fighting more or were there any client traceability issues that we should be thinking
about?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So, your question about the CareSpeak and
if there is a GAAP fair value calculation and has to be done and is based on future projections, we lowered our projections for
2020 specifically related to CareSpeak, that product line a little bit. We still expect them to make their whole earnout, but that
is not the way GAAP works.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good GAAP management, and this is Will,
on the second question, the penetration of market was so great that they decided they just did not need to continue to spend on
it. That is ultimately the case and while disappointed that it is their call and we still have a very good relationship with that
client and expect revenue to increase into next year compared to this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew D&rsquo;Silva:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, there was some client reporting issues
that happened, not caused by anything you did, just something macro in the market and I was curious if any of those three customers
that had kind of that anomaly in the third quarter were that customer as I believe you were allocating some Q1 benefits back in
to the back half of the year?</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now that was a temporary, basically a reporting
requirement that we were able to address, has not been an issue through the year. This was strictly an isolated patent expiration
issue, just stopped spending early unfortunately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew D&rsquo;Silva:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay and then as it relates to RMDY Health,
can you give a little bit of good color on the market there, I am just curious you give a little insight, how it is differentiated
from Livongo, it is providing and will it be actually included in your enterprise package as well?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I can start and then maybe Miriam could
add, so the differentiation from Livongo is basically Livongo is specific content, specific method to enable adherence related
activities and so you buy into their way, which is very impressive and very effective as they have shown, it is a great business.
We bought RMDY because it basically can enable anyone to do anything they want with healthcare and focused on adherence, and so
we can almost think of it like a Wix for healthcare, it is just a very easy way to, in a SaaS model, allow someone with content
and members to enable them digitally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are obviously the very big players
and then there is a big middle market that are all desperate to be digital because their members now are requiring it and we think
that is a great opportunity for RMDY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Miriam Paramore:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I will just&mdash;and it&rsquo;s Miriam&mdash;I&rsquo;ll
way in just a little bit. The Livongo took also a disease specific approach, so they took a combined sort of hardware and content
approach, they actually created their own devices and started from the hardware side before they went into the content and the
services side, so they are a combined technology and services company with diabetic nurse educators on the back end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our strategy is to stay a focused technology
company and not to include back end call centers and things like that, so that is the point of differentiation. But broadly speaking,
the solutions are trying to help ease the pain of care management or disease management and use digital technology, current contemporary
technology to do that. The last thing I would say is that our solution set is not disease specific, it is not therapeutic area
specific, but can be used for any, and the focus is more about enabling an organization whether that be a payer or pharma who has
clinical pathways and a bunch of content that is research driven that already exists, but is offered up via phone or coaching advice
or acceleration to move that into contemporary technology communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Andrew D&rsquo;Silva:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, great. I will take rest of my questions
offline, but thank you very much and good luck closing out the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks Andy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will hear next from Richard Baldry with
ROTH Capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Richard Baldry:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks. I am curious if you could talk
about what typical contracts look like, what brands, like I am surprised that mid year someone can drop out sort of or alter their
spending pattern, so quickly so, that are not minimums involved or you know at certain price points for volumes, guarantees or
is it very optional for the customers on the fly to change their spend pattern?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks for the question Richard. Typically,
the agreements that we got are 12 month agreements, we will open an SOW and then revenue was recognized as we deliver on that revenue
throughout the year. So in the case of an LOE and client pulling back, basically they move that brand out, that was not a guarantee
in that specific agreement to be able to have significant claw back to replace that revenue and so that is the impact that we felt
and going forward we have adjusted our contracting language to account for that. Also, Will sort of alluded to the recurring revenue
model, which is a little bit of a switch from the model that we have had in the past as far as remuneration of contracts, etc.,
so we are preventing that sort of revenue claw back issue from occurring in the revenue drop out, makes sense?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Richard Baldry:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. When you talk about the revenues pushing
out of the second half of &lsquo;19 into 2020, does that mean that you think that spend will be incremental to which you otherwise
would have expected from those clients in 2020, or it is really sort of&mdash;it just delays the beginning of that climb into a
later period?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I will let Steve answer as well, but now
that, that is a gigantic company, we view it is nothing but upside. They have so many needs, we are at the table. Often when these
things happen, you actually gain a little bit more relationship because they actually want to do the work and for their reasons
cannot, so you stay close to it and in staying close and having a broader footprint in terms of brands and disease areas, we think
that is going to be a terrific opportunity for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I totally agree it will be upside opportunity
on the year, for what we would initially have anticipated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Richard Baldry:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given enthusiasm around the additional
head count you put in commercial aside, can you talk about whether you think you&rsquo;d continue to add to that head count sort of early
in 2020 or entering the year? Or you feel like the team you have right now should gel a bit more before you add on top of it?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think we will continue to add as we need
to add Richard, so what we have done a good job of is bringing the right people in at the right time, getting them ramped, trained,
letting them prove out their worth in the market and adding as we go. What we do not want to do, which is what you are alluding
to is just adding heads for the sake of adding head count, I think we are very disciplined about that, so when we have the correct
people to bring on board, we execute, bring them on board when the opportunity is there and outside of that, we are continually
scoping and looking for new talent and continue to bring people in as is necessary, but not prematurely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Richard Baldry:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. And I&rsquo;m not sure if you&rsquo;d be willing
to answer this, but when you talk about expecting strong growth in the fourth quarter year-over-year, if I look at the last 4 quarters,
growth has ranged anywhere from, putting the third quarter aside, growth ranged anywhere from 27% to 75%. So there&rsquo;s a lot of room
there. Now that we&rsquo;ve seen that revenues can swing pretty meaningfully, is there any way to kind of gauge or narrow that band down
on what you&rsquo;d expect in the fourth quarter maybe versus any of your prior periods?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Richard. Yes, it is tough, because
we obviously do not give guidance, so it is a little tricky, but I think if you go back and look at earnings calls, as everyone
who knows me, knows, I am consistent and I try not to be emotional on these, so that you actually believe me and I think if you
go back and look what we have referred to a strong, you will be able to get a good range. We obviously would not say that lightly
because the last thing you want to do as a company is disappoint twice in a row. We feel really good about that; the team is humming,
our morale is high.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We really run the Company, not around the
quarterly calls, we have run it around our clients and that is really important. We are disappointed, we are not hiding from it,
we are right in front of it, but feel really good about the next quarter and frankly 2020 as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Richard Baldry:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks, Rich.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Next from William Blair, we will move to
Ryan Daniels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ryan Daniels:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks for taking the questions. Will,
maybe one for you, a follow-up on Q4. At this point, how visible is your revenue stream for the fourth quarter versus how much
you need to kind of go get or see clients flushing through some year-end budget. So what&rsquo;s the visibility to your internal target
at this point?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Visibility on the internal target is good.
It will be better in 20 days because you get a lot of upsell opportunity in end of November and early December. We are ready for&mdash;we
are already seeing some of it. Success often begets success and our clients do not watch our quarterly calls, they are meaningless
to them. They are really deliberate all our service and that we are doing a great job, so I feel pretty good about the Q4, obviously
we have some new businesses, we are still learning visibility on those, but because they are more recurring in nature, there is
good visibility there.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You know, we talked about it Ryan, it is&mdash;
when we came in, we had no visibility and then we felt like we had a quarter and we got to about six months, you can still have
disruption. We have talked about these risk factors and we are working really hard on getting rid of those risk factors, but it
is going to take time, but just to answer directly to your question, we have pretty good visibility on Q4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ryan Daniels:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. That&rsquo;s very helpful. And then if
we look at the revenue hiccup in the quarter, especially as it relates to the merger between the two entities, the larger dollar
item. Is that a contract where you are just hoping that the larger organization needs to kind of engage more third-party help?
Or have you actually had the contractual agreements or seen RFPs, which indicates that this is definitely just a blip or a transitory/timing
issue versus something that could extend into 2020?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I will take that one right, this is
Steve. So, we actually do have the RFPs that we responded to. In addition to this sort of this revenue blip of the merger, that
specific company, one of the clients had a drug recall which added sort of a near-term pain and so it really caused them to pause
and focus on that recall and executing it effectively so the RFPs were paused, but we have those RFPs and receiving and we are
progressing those along very nicely. So, as Will said, I do believe it is a pause, not a close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ryan Daniels:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. And then last question and I&rsquo;ll hop
off. If we think of the $70 million in the pipeline and the typical close rate, 35% to 50%, how much of that could actually flush
into 2020 sales? So just, let&rsquo;s say, we use basic math, $70 million, 50% is $35 million, how much of that if it&rsquo;s signed this year
would actually go into 2020 sales versus being something that might be a multiyear contract? How should we view that metric you
just gave us? Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. It&rsquo;s a great question. I&rsquo;ll try not
to provide any guidance on answering the question. But essentially, we&mdash;the $70 million represents opportunities created in
the period versus $30-some-odd million from previous year, which were opportunities created previous year. So some of those will
push into 2020, no question. I think we&rsquo;ve got great runway rather on having a good opening position for 2020, which is what we
are laser-focused on in addition to executing a great Q4. That&rsquo;s really sort of at the heart of building one of these businesses
and scaling it to where we are trying to track. So hopefully that, in a roundabout way, answers your question without providing
specific guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ryan Daniels:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. Thank you for taking it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You got it, thanks Ryan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We&rsquo;ll hear now from Bruce Goldfarb with
Lake Street Capital Markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Bruce Goldfarb:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you for taking my call, Miriam, Steve,
Will, Doug, congrats on all your progress and success. I just have a couple of questions. You previously mentioned the potential
for broader enterprise engagements with your pharma customers, can you give us any update on how these discussions are progressing?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, happy to, this is Steve. We have got
several and by several, we are progressing five really key deals right now, that are, you know, I would say they are in mid stages,
mid to late stages comprised of multiple solutions across our platforms, which is really what we are driving for. I do not know
how much more you want to hear about it than that, but that is&mdash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Bruce Goldfarb:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Those ones you talked about earlier, you
know, so you quantify them maybe around $30 million, are those different?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, those are that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Bruce Goldfarb:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I think just to clarify because we talked
about a little bit back in Q2 and like that, subsequent conversation (inaudible) investor. By enterprise, that is really defined
by taking our either complete solution set and bringing it to a brand, or taking multiple brands around a specific solution and
dominating that. It just gives you the opportunity to engage at a deeper level with the client, it is a bigger engagement and it
is really tied to the impact of that overall solution set. We will keep defining that over time, but it is really important to
get above the tactical selling and we still do it, but you can&rsquo;t just jump to it overnight, but it is really what our client
prefers because it is more meaningful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Just to give you an example, one customer
this year we have gotten basically an enterprise situation: last year, they did full revenues of $774,000; this year, they are
going to be just about $4 million, so that gives you an idea of scale. That is why it is important.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Bruce Goldfarb:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And then you mentioned on the call that,
M&amp;A is something you are considering. Are there certain capabilities or things you are sort of targeting, that you would like
to add to the portfolio?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a pretty tight screen on what we
are going to look at, so anything that would expand reach to HCPs or patients, any kind of solution set that could get us connected
to pharmacy and then any kind of digital enablement of communication that either does not have access to pharma or to payers, but
they have technology. We are really focused on the two we have right now and becoming one company and doing I think a very good
job of that with Miriam leading the way, but that is our screen. We are going to stay in those guard rails.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Bruce Goldfarb:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Great, thank you, that&rsquo;s all I have.
Congrats again.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Miriam Paramore:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will move onto Josh Goldberg with G2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Josh Goldberg:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I had a couple of quick questions and I
appreciate the thoroughness of the call. And Steve, welcome. I guess I&rsquo;ll start by just asking&mdash; obviously your business is
an advertising driven business, that the budgets can change pretty quickly as we&rsquo;ve seen in this quarter. It seems to me like you&rsquo;re
trying to get some more visibility into next year by some of these enterprise contracts if they sort of grab bag of orders that
you might get which is probably what gives you less visibility in &lsquo;19 than what you might have in &lsquo;20. The pipeline as well looks
exciting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So I guess it seems like a lot of advertising,
interim advertising in health care. Generally, you get a better sense sort of January time frame. Do you have any sense from us
based on the pipeline or based on your conversations that&mdash;you know, that comment about 25% to 50% or 70% of your business,
the pipeline coming through? I mean you&rsquo;re implying a nice growth next year. Can you give us any sort of comments or commentary
that could give us confidence that we&rsquo;re looking at a growth year?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, I think&mdash;thanks, Josh. Good question.
And two things I&rsquo;d like to say, and then maybe, Steve, if you want to jump in, you can. We&rsquo;ve got a ton of credibility right now
with our client set. And I think that, that is very meaningful in pharma. I was always asked 2 years ago, well, why aren&rsquo;t you
a $100 million company. And then a year ago, why aren&rsquo;t you a $150 million. And it&rsquo;s because pharma doesn&rsquo;t move fast. You have
to prove yourself. You have to have measurement of that proof. And then I would say the second point&mdash;and we&rsquo;ve done that,
I think we&rsquo;ve done that with the best manufacturers you can do it with. So we have just a great, solid base.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The second is, and Steve can talk to this
more, is we&rsquo;ve repositioned how we&rsquo;re selling to our client in a way that is in their language, it&rsquo;s more meaningful to their pain
points, but it&rsquo;s the same solution set. So as investors, you don&rsquo;t have to worry about we&rsquo;re going and creating new stuff. We&rsquo;re
just delivering it in a different way that connects into their thought process, their budget cycle. And my hat&rsquo;s off to Steve
and the sales team because we&rsquo;ve really brought that into this business. And I think it&rsquo;s significantly changing our profile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. I mean just to add, Josh, just around
the question around visibility specifically into January. I mean the way that our contracts work and the way that we sell, right,
we sell a contract, we open up a PO and then revenue is recognized as we distribute over the months, right? So we have fairly good
visibility into 2020 based on the sales that we will make in the fourth quarter, which will not be revenue recognized sales for
2020, but the revenue will start to drop in Q1 of next year, starting in January. We&rsquo;ve now got in our business, developed
forward-looking revenue metrics to help us guide and orient the business in a more meaningful way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Miriam Paramore:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Let me just add one thing. This is Miriam.
Don&rsquo;t forget our supply-side win, we have a huge, huge advantage with NewCrop. And our competitors can&rsquo;t sell in there. So that
market share is shifting, period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Miriam Paramore:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of it. And so it&rsquo;s&mdash;that by itself
has&mdash;is a huge driver of growth for next year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Is that helpful Josh?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Josh Goldberg:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. Do you think that having enterprise
contracts also is something that will give us better visibility and the fact that this NewCrop opportunity gives you more supply,
will kind of catalyze that? Or we&rsquo;re still going to kind of walk through 12 months from now and still have a sense of what the
fourth quarter might or might not be if you think we&rsquo;ll have better visibility 9 to 12 months from now for next year?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. I mean that is the reason for the
enterprise push, right, is to develop more predictive revenue streams. So when you think about what we&rsquo;re doing there, I think,
number one, it enables us to do a 12-month contract, right, instead of short term or transactional stuff, as Will has said and
you&rsquo;ve heard him say. Also allows us to enter into now multiyear agreements, which we&rsquo;ve got a couple in the pipeline right now,
including some of those enterprise deals. So that&rsquo;s really an opportunity for us to actually be very predictive around our revenue
and build that recurring model that you&rsquo;ve been hearing us talk about.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Miriam Paramore:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And in addition, the RMDY revenue&mdash;
historical RMDY revenue is SaaS-based revenue, highly predictable. As that revenue builds, that just increases visibility as well.
So those are three kind of factors: multiyear, NewCrop supply control and SaaS-based recurring that improve our predictability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Josh Goldberg:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks Josh.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our next question will be from Ron Chez,
Private Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ron Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good afternoon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hey Ron.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Good afternoon, Will. I have a couple of
quick questions and then a longer one. How much of the expense increase in the third quarter was non-recurring, I wrote down $1.1
million, am I right about that Doug?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes correct, that is the number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ron Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So, expenses without these things would
have been lower by $1.1 correct?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ron Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, and what is the NewCrop advantage,
it is another set of physicians, HCPs, is that it, I mean, I know exclusive, but how is that different than some other EHR capability?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Miriam Paramore:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ron, this is Miriam, I will take that.
First of all, exclusivity is the headline and sub-headline, but the Innovation Lab is really the growth engine if you will or expansion
and new monetization, so we have an established EHR network, that is a largest EHR network, digital EHR communication network in
the marketplace and we are monetizing that with pharma, we are also going to monetize that with payers, but within pharma, we are
going to find new ways to monetize the same railroad track through this Innovation Lab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a couple of pilots that we are
finishing the design elements on right now, within that hot bed of 65,000 providers. We are going to prove in those pilots, value
creation; and once we prove value creation inside of NewCrop, because they have agreed to incubate with us, then we can look to
expand and scale that to multiple EHRs, multiple e-prescribing. But you have to have a place to start to show that you&rsquo;re creating
value and there&rsquo;s ongoing revenue to go get. So that&rsquo;s different.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NewCrop delivers what, 65,000 HCPs?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Miriam Paramore:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">They do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">That you&rsquo;re going to sell? Are they going
to be sold financial messaging, brand messaging? You&rsquo;re going to sell into there?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Miriam Paramore:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So we don&rsquo;t sell into our EHR channels.
They are our partners. So we have business-to-business agreements with the EHR channel and we light up as many types of messages
or commerce as we can with them. So with the example of NewCrop, we can do all three of the messaging types that drive our revenue.
So we&rsquo;re going to fill up all of those&ndash;that pipe with all of those messages that we can get from pharma in the traditional
business sense of OptimizeRx. But we&rsquo;re also going to incubate and find new types of digital commerce to drive from pharma to NewCrop
users, and from payers to NewCrop through this lab environment. So it&rsquo;s just that, that beautiful utilization; as much traffic
as you can over the same site and monetize every piece of traffic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I&rsquo;ll ask a question about that offline,
okay?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Miriam Paramore:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Did you ever mention RMDY&rsquo;s run rate?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We did not. No.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And is it what you expect it to be right
now? I mean, there&rsquo;s (cross talking).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. We&rsquo;re a couple of weeks in. We see
a lot of opportunity there. It&rsquo;s primarily on the payer wellness, medtech side, all very good clients that have returned. So we
expect to be able to continue to grow that. And I think there&rsquo;s also an ability to introduce this delivery to pharma at a certain
stage or prelaunch stage. So yes, we feel good about it, the team is excellent, and it really adds a lot of muscle to our Company
from a technology standpoint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without seeing what their sales have been
or would be this year, do you expect, however you define that, do you expect explosive growth from RMDY? Explosive to me is between
50% and 100% next year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The answer is yes?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The answer is yes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay. And this is the longer question.
Steve, you touched on this. If you can&mdash;well, maybe it&rsquo;s the client that you were talking about without name, that client
was how much in &lsquo;18 that in &lsquo;19 is $4 million?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes. So in &lsquo;18 full year, they were $774,000,
then full year 2019 they&rsquo;re going to be close to $4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And is that because of additional brands?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">More several&mdash;it&rsquo;s additional brands
coming on and additional solutions per brand. So if you think about sort of&mdash;traditionally, we had started out with financial
messaging. We&rsquo;ve now commercialized new solutions like brand messaging, clinical messaging, etc. It will represent enterprise suite
of solutions, Ron, and that&rsquo;s the growth that we&rsquo;ve chatted about on other calls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One more question attending to that. So
you said $774,000 and $4 million, what&rsquo;s a ballpark expectation for growth into &lsquo;20, same client?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Same client? I think probably between,
I&rsquo;d say, between $6 million and $7 million is a good number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Okay, are there other clients?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So that&rsquo;s just giving you&mdash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You guys have other clients like that?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yes, there are multiple, as I mentioned
earlier, there are multiple late stage or mid stage enterprise deals that are representative of that same sort of pattern we see
when buying those enterprise deals across the solution set.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">So you expect that revenue to grow whatever
in ballpark, and that&rsquo;s as a result of enterprise solutions being provided with the various delivery of the components that you
have?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It&rsquo;s a direct result of that, yes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I have other questions. I&rsquo;ll stop,
though.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stephen Silvestro:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks Ron.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks Ron.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><IMG SRC="ex99-1_002.jpg" ALT=""></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And at this time, I&rsquo;d like to turn things
back to Mr. Febbo for any closing remarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thanks to everyone for joining the call.
We had actually a record number of people, which is wonderful. If you could take just one thing away from our discussion I hope
it&rsquo;s the understanding of our potential for continued strong growth, while generating tremendous value for everybody. And beyond
the numbers, I hope you see that we&rsquo;re really creating a unique corporate culture dedicated to do something that matters in health
care, very topical, makes a difference in people&rsquo;s lives from patients to physicians and beyond.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When we can grow at these levels, and I
will highlight that we&rsquo;re still on a very good growth rate for this year, it&rsquo;s always disappointing to see a quarter that&rsquo;s not
what you want it to be. It&rsquo;s also for our team a kick towards even being more aggressive. And we&rsquo;ve got a team that is capable
for scaling this business to a very, very large business. And I think all that combined translates into a great opportunity for
our stakeholders, and I hope you all agree. Have a good night, and I look forward to talking to you all. Take care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and gentlemen, now, before we conclude
today&rsquo;s call, I would like to report the Company&rsquo;s Safe Harbor statement that includes important cautions regarding forward-looking
statements made during today&rsquo;s call. Statements made by Management during today&rsquo;s call may contain forward-looking statements within
the definition of Section 27A in the Securities Act of 1933 as amended and Section 21E of the Securities Act of 1934 as amended.
These forward-looking statements should not be used to make an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The words anticipate, estimate, expect,
possible and seeking and similar expressions identify forward-looking statements, and they speak only to the date that statements
were made. Such forward-looking statements in this presentation include statements regarding estimation of total addressable market
size, market penetration, revenue growth, gross margin, operating expenses, profitability, cash flow, technology, investments,
growth opportunities, acquisitions, upcoming announcements and the need for raising additional capital. They also include the Management&rsquo;s
expectations for the rest of the year and adoption of the Company&rsquo;s digital health platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise. Forward-looking
statements are inherently subject to risk and uncertainties, some of which cannot be predicted or quantified. Future events and
actual results could differ materially from these set forth and or contemplated by underlying forward-looking statements. Risks
and uncertainties to which forward-looking statements are subject to could affect business and financial results are included in
the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018. This form is available on the Company&rsquo;s website
and on the SEC website at sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we end today&rsquo;s conference, I would
like to remind everyone that this call will be available for replay starting later this evening and running through November 26.
Please refer to today&rsquo;s press release for dial-in replay instructions available via the Company&rsquo;s website at www.optimizerx.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you for joining us today. That concludes
today&rsquo;s conference. You may now disconnect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">19</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ViaVid has made considerable efforts to
provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of
the conference call. This transcript is being made available for information purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1-888-562-0262 1-604-929-1352 www.viavid.com</P>

<P STYLE="margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %G ?<# 2(  A$! Q$!_\0
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M71_PVM\5/^@!\/\ _P %7B/_ .:NOI"FE0?8^O\ CZUV_P!D_P#3_P#\I?\
MVYY+XD?3!7_[F+?^X3YQ_P"&UOBI_P! #X?_ /@J\1__ #5T?\-K?%3_ * '
MP_\ _!5XC_\ FKKZ)((ZTE']D_\ 3_\ \I?_ &Y'^L^MG@K?]S'_ -Q/G?\
MX;6^*G_0 ^'_ /X*O$?_ ,U='_#:WQ4_Z 'P_P#_  5>(_\ YJZ^AF4'V/\
M/ZU$01P:/[)_Z?\ _E+_ .W!\3-?\P5UT:Q&G_ID^?O^&UOBI_T /A__ ."K
MQ'_\U='_  VM\5/^@!\/_P#P5>(__FKKZ IC)GD<>WK_ (4UE*>^(M_W"_\
MN@O]:/\ J"_\N/\ [B>!?\-K?%3_ * 'P_\ _!5XC_\ FKH_X;6^*G_0 ^'_
M /X*O$?_ ,U=>\$8X-%4\F:5UB+_ /<+\OWFH?ZT?]07_EQ_]Q/!_P#AM;XJ
M?] #X?\ _@J\1_\ S5T?\-K?%3_H ?#_ /\ !5XC_P#FKKW1D[C\O\/\/_U5
M'0LG3VQ/R]EM_P"5!/BAK; W_P"YG_[@>'_\-K?%3_H ?#__ ,%7B/\ ^:NC
M_AM;XJ?] #X?_P#@J\1__-77N!&>#43)CD<^W<?XT_[&_P"HG_RE_P#="/\
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M "A_]U,Y<<-?\RNZ[_7/_O8YC_AM;XJ?] #X?_\ @J\1_P#S5T?\-K?%3_H
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M!\/_ /P5>(__ )JZ/^&UOBI_T /A_P#^"KQ'_P#-77F+)^(_4?Y]1[U7>/\
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M?_WR9_\ $9?^J=_\RO\ ^#SZB_X;6^*G_0 ^'_\ X*O$?_S5T?\ #:WQ4_Z
M'P__ /!5XC_^:NOE1D]!@^G8_P"?R_G41&.#3_U%_P"II_Y9_P#WR)^,S6W#
ME_\ NK?_ (//K#_AM;XJ?] #X?\ _@J\1_\ S5T?\-K?%3_H ?#_ /\ !5XC
M_P#FKKY+9.X_+_"HZK_42ZNLTOW7U/7_ -2=2/\ B-/_ %3G_F6__!Y]<?\
M#:WQ4_Z 'P__ /!5XC_^:NC_ (;6^*G_ $ /A_\ ^"KQ'_\ -77R/4;)W'Y?
MX4UP&GMFO_EE_P#?1#\:VM^&O_,O_P#@X^O/^&UOBI_T /A__P""KQ'_ /-7
M1_PVM\5/^@!\/_\ P5>(_P#YJZ^/R,\&HF0CD<CT[_\ UZ?^H7_4U_\ ++_[
MZ%_Q&S_JFO\ S+__ (./L7_AM;XJ?] #X?\ _@J\1_\ S5T?\-K?%3_H ?#_
M /\ !5XC_P#FKKXW(!ZU$R$<CD?RH_U"_P"IK_Y9?_?0?\1L_P"J:_\ ,O\
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M=_\ Z]:)M:HYIP^3[]'_ %]YF21D'D8/8]C^/?\ F._I55TY]#^A_P ^M;)
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M'^#]#*4&M5JOQ159 >1P?YU&01P:M,I'3D?R^O\ C49 /6J(*K(#R.#Z=O\
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MY0WLO5/^OZZ&5)$"/F&0.A'!&?\ /N#QFJ;QLGN/7'\^N/Z_F!LLG7'!]/\
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MMT?H05&R=Q^7^%3%2/IV--IIM;$-6T97H(SP:F90?8^O^/K41!'6M+QGY/\
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MFOZ_/Y&,Z?B/7N/\_P"?2J[IZ\CU]/\ /Y=*U7C()&,$=1_G_P#4?UJLT?7
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MA;_R3+X<_P#8B>$?_4?T^BOP[%_[WB_^PK%?^I.)/[-RO_D699_V+<N_]5^
M/CK]NC_FEO\ W.__ +J-1>"WQX1\*]B/#FACZ_\ $LM?\XJ7]NC_ )I;_P!S
MO_[J-4/!SX\)>%P>1_PCNB?7_D&6M>EDJ;JXBW2E#_TXSP.+O]VP7_835_\
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M2@@]*J*^>OX'L?\ /Y5(#CD4C:,NJ?\ 7F6E8CCJ/\]*E!!&1557SP>#^E2
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M,^?-\7S^WK3EB*M>"M5JXBLZ5"-18>C[>O7JNC"U6I*Z4/\ ,A^ 7BG]N_\
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M_P""?'P_\.WGBOQ=^R+^REH^@Z?<:5:W=_\ \,U_#&_$4^M:M8Z%ID?V72_
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MV/\ G\_6J<D()R/E;K['_/J/?()K1/JCDG2:VU7X?UY/Y'Z[?#+CX;_#X?\
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M:J726J_%%H'/(HJ ,1T_+M4P8'Z]Q4W<=]8]^J]2TVO[T>_5>I*K]C^?^/\
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M3X4O?AKX6O?"OB33+'XDK)XC\+^$;G6KS4]+\*Z'KUY?6$5]I][)X>U"[AN
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M8T_L[5M&M_%K7VIZ;?OX)U+XBO9_9G9+ZTAO[25O$4L,<L>EI%<6EPUI;&>
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MU&3GT/\ /_/J/>J[)SZ']#_GUK6,FMM5VZ'/*&]EZI_U^!^KWPVX^'7@$?\
M4E^%O_3'8T4OPX&/AYX#'IX,\+C_ ,H=C17X[BO]YQ/_ &$XG_U(KG]49?\
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MJE)K3==F0XI^O<H.GKR/4=O\*@92OT]:TF3/3\NWX?YQ5=DZX_$?S_\ U?\
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M'N#^(J17QU_ ]_QJFC^GXC_/\ZG# _7N*EI/<Z(S[ZKO_7_#EU7Z9_ _R_\
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M$RD<]1_GK4Y!'6DIV:UCJNW^0%>D(!ZU,R=Q^7^'^<5%5)I_JNJ,Y0ZK[O\
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M_7\Q_G_Z]6G?6.CZQ>S]#.4+[?=T_K\#*:/K@9'<?Y__ %U79.N.0>W^>O\
M.M1T]>#Z^O\ G\^E5W3\#Z]C_G_/I5J5_)KH82AVT?;_ ",IDX]1^H_SZU79
M/Q'ZC_/J/>M1TY]#^A_SZU79/P/Z'_/M6BDG\6_22W^9C**>^C_$RW3@]Q^H
M_P ^M5G3\1Z]Q_G_ #Z5J,GH,'T['_/Y?SJNR=<<$=O\]/Y5:DU:_P I+8PG
M#O\ )K^OP,J2($?,,@=".",_Y]P>,U1DB*]1D?WAVY[^G7ITYX)K;:/K@8/<
M?Y__ %56:/K@?4'W^O\ (UM&=]_OZ?U^!S3AWWZ-=?Z^\_1GP&,>!O!@]/"?
MAT?^4>SHIW@88\$^#@.,>%O#PQ]-)M**_,<1_O&(_P"O]?\ ]/UC^B,%_N6"
M_P"P/!_^HF%/BC]NC_FEO_<[_P#NHUX+H3XT;2>X&F6 (_[=8O\ /O\ R]Z_
M;H_YI;_W._\ [J-?/&B3 :5I8/RD:=9 'L?]&B'/IQUSQUSCI7T7"T>;$8S_
M +!Z7_I]GP7B/+EP65:V_P!MQ-O_  CB=0C^G([CN/\ /Y=:LI)^(].X_P _
MEZ5E*_J<'U['_/Y?RJRK_@?T/^?>OL6FM&?E49IZ/1_@S7CF(&#\R]/<?Y]#
M[8(%74D!'!R/;J/;_P"L>1^E8:/SZ']#_GTJU'(0>#@]QV/X=_YCMZUG*">J
MT?X,VC-K1ZK\4; .>13U?L>??T_Q_G5&.8-TX;^Z><X]^_Z'KVYJRK ^Q]/\
M/6LVFM&;QG\UWZK^OO-&.;& W([,.O7OZ_4<\=R:NJ_ SR.QZ_3Z_7_]=8@8
MCZ>E68Y2O0\=2I_S^H]L^E9RA?5:/MT_X!TQGWU7?K_7XFL"1R#CT(/]15E)
M@>'P#V/8_7T/?/ ^F.<V.4'H?JIZCWQ_49'/K5@$'I6371G1&??5=_\ /^KF
MB#CD5*K^IP?7L?\ /Y?RK/20IP>5ST[CZ?SQT^F2:LJRL,@_4=Q]1V_KVK.4
M.J^[_(U3ZHT%?\#^A_S[U85@>O!_G]/\*S%<C@\C^53J_'J/U'^?2LS2,^_W
M_P"9?!(Z?Y^M3(_IP?3U_P _GUJFK],\@]_\]?YU*#W'X5,HI^O<Z(S[_>7T
M?TZ^A[_XU.&#?7TK-5\=?S[_ (_YS5A7Z9_ _P O_P!?_P"NLFFMS:,FO-=O
M\B\&(^G<5^<_[2G_  5U_P""</[(7Q4TSX)?M#_M5>!? 'Q2U*6SBF\(1:1X
MX\97GAQM1^PM8MX\O? /A7Q3I/PXBN[?4K._@G\?:AX:ADTN1]660Z9;W%W%
M^B(<D$9Y(.#VR1QGD?IC\.M?S7_\$Y/VHOV-?V4M _;U^$G[;OQD^!OP1_:7
M?]LG]I'Q=\;]%^/7B'PQX'\6_%;P+XS\0W6L_#37]$MO&U]'??%+P?J_PYN-
M/MO#6E^&Y/$<=GI[QZ6EA&]Y"+WAK8B4,14I^UPE"&'RK%9K+ZU*<7C7AL=@
ML$\#AYPG&5.5.GC'F.,KTZ6-KT,#3C*A@*[G4J4?5PE"G4P\J[H8[%2EC\'E
M\88%0<L+];P^.KK&XE2HU^:DZF#A@,+2:P]&OF&(A2KXW#TU!5?Z//!WC+PK
MX_\ "WA[QQX%\2:'XQ\&>+-(L=?\,>*?#.J66M^'_$&B:I;I=Z=JVC:OITUQ
M8ZCI][;21SVUW:SRP31N&1R#FM36=>T/PYI=UK?B+6=*T#1K%4>^U;6M0M-*
MTRS265((VN[^^F@M;=9)I(X4::5 \LB1J2SJ#_$/X;^('C?X._LF?\$P[!OV
MJ_BW_P $_?V8OCY_P4(_:]O?#/C[P[XG3X92>&/V1?'$WCC7OA'9:[;>,[2[
M\$67AS4+6\@O_!NH>._"=UX<\%P:_H_BVWTFWDTNVO:\K_::U76_BU^R)^UI
M\,S_ ,% /VBOVBOV3OV-_P#@HI^QQI7P4_:YO?CKH?B#4_%GA?XM3^%?^%F:
M?\1OCEIVDR:%\3;?X$:[X@B\5>"?&\MU#8>$?%:Z-JT+C2-.T[1X-'656M4A
M1P]7#RAC,'AYX?'5\+1Q&$53%^'%#,:.9SBU0RW%Y=_Q$;!8=+,(X:CC,=E6
M;0@Z-/ XM4M7E_LX>TGB8U8J.,DJ^$PN*K4\3&E6\0,-@:N"A%SEF$,=/@'$
MUYTL#4Q-?#83,L#5MB/;X:57^W'0/VC_ (,>*/CWX_\ V8="\9?;OCE\+O!/
MA3XB^._!'_"/>*[;^P_!OCBYNK3POK/_  DMYH=OX0U/^U+BRN8_[/T?7]0U
M6R\O?J-C:(\;/[FKD<'D?RK^-']L[]H#XQ?"H?\ !4/PK\$/VR_VA/&WP_\
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MP _X*<?M#?M)W_A/]FGXTW'[&?[#W[2O[<WAS]J7]H37H_"VC_;+S]HGXN_
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M3-A7X]1^H_SZ595^F>0>_P#GK_.LB.;=QT;N.Q^GKZX/([9QFK:/Z<'T]?\
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MT7P^?V7_ -G9M \.> O$?PK\/:(?@I\-3I&@_##QA,]SXN^'&C::?#/V+2_
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MJM.VL=5UCU7H92AVU7;^O^',MT]?P/\ G^1]\57=/7\#_G^5:C)UQ^(_G_\
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M-Z?#\<%2P^'C5A%^UQF?4Z+JSK>S6'H+$\LJF*P^$/Z$U8CKR/Y?3_"IU?\
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M\2_$0L]'TKXCRW[:[X<\,_!_QMJ%E]M\7Z;X'UR_^)&A^$+ZVT73_%%WJ_\
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M/R?];GVWX0X\)^%QZ>'=$_\ 3;;44[PE_P BKX9_[%_1O_3=;45\!6_C5O\
MK]5_].U3]KPO^ZX7_L%PW_J-ASX?_;H_YI;_ -SO_P"ZC7R!8/\ Z':=P+:
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M][X[U2'6=3L]1?5_A1X<GN='\ :YH%W;R^&=9\.6<\@LM2T:Y,C-+(['P/\
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M-]O13O#/'AOP^/31-)_](+>BOB:O\6K_ -?:O_IRH?KN&_W;#?\ 8/A__3%
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M.L>$M/\ )N)M8LKM=#CUNZGA]M^.'_!/O]OK1?B;^UI8?L8_'']EOPO^S_\
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MVJ[?U_PQJQRD'C\5/0_Y]>OKQP;B.KCC@XY'<?XCW'MG%8ROTS^!_E_^O_\
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MZHVC/Y/OT?\ 7W&@K$<=1_GI5A'X]1^H_P ^E4E?/!X/Z5("1R*SE%/5:/\
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M\?U&#QZ5>CE#=#SU*G_/ZCVSZ5D ]P?Q%2*_(SP>QZ?3Z?7_ /742BGY/O\
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M\?YTI0ZQ^[_(LF!(Z5*&#?7TJ&BLRHR:\UV_R+%.#%?IZ5"K]C^?^/\ C_\
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MB@&D]SZ9\/\ _(!T3_L$:;_Z1PT4N@?\@+1?^P3IW_I'#17R53^)4_Z^5/\
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M ,RM%%2^(<[>^9XO_P "I_\ S./_ %%X._Z)S+/_  77_P#FT/\ ABSX6_\
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M_P#FDD'[-O@8=-6\6?C?:/\ _**GC]G'P0/^8KXK^AOM(_\ E'111_:V9?\
M0;7_ / H?_*A_P"K/#__ $*,'_X!5_\ FDE7]G;P4@P-5\5$>AO=(P/I_P 2
M,']<=>*D'[/?@P?\Q3Q0?K>Z5_\ *6BBI_M7,7_S&5_OA_\ *BO]6L@7_,IP
M?_@%7_YI%_X9\\&?]!/Q/_X&Z5_\I:</V?\ P:!C^T_$_P"-[I7_ ,I:**/[
M4S'_ *#*_P#X%'_Y4/\ U=R+_H5X3_P&I_\ -!,OP%\( 8_M/Q*?=KS2R?S_
M +&'ZU(/@3X1'_,2\2'ZWFF?_*>BBE_:6/\ ^@NM]\?_ )65_J_DG_0LPO\
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'DDEY)'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  @ K\# 2(  A$! Q$!_\0
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M_P *.8+5-I_\Q[ZIGC[>+/BK_#\1O'/_ (4VKG'_ ),Y-0GQA\5A_P U%\=
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M_C<#_L8]3/Z_:,5VA\(D_P#+/\,#'ZYJ)O"./^66/R_0<8_$52K9=UP>"_\
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M+4O%?[./[1FA>'_'_P 1OCM^TK^T%%\$?#?B?XQ_%OQ=X<\/^+D\ _#/XO\
MAKQE;^$/ TO@SPOX0\#?"WPWX5LI?&OBK0-(\%^$M*-[XTU2;6]9N-9UJ:VO
M(?8M7_85\+>*O"GQ/MO''[0'Q_\ '7Q6^)>K? O4U^/GB74OAH?B'X)M_P!F
M7XD#XL_ S0/!>AZ/\-=(^%]AX>\(>/'U'Q+JVG7_ ( U%_&VKZ_K]]XJN=2>
M[L5TSV3_ (6WX8_Y^+O_ ,!6_P#BJ>/BYX6'_+>\'TMG_P#B^:3P63<SE[6@
M[P4.5U9.-KU&Y?$FZDG4ES5)N<UHXRB]319QQ8H0@L+CERU75YXX2"G?EH1C
M35H<L:$%AZ:C0IPIT6KJ=.HG8Y+P+^Q[\,? GQET3XXV/B[Q[J/C#1/BO^T!
M\8UMM1OO#HT6^\5_M'>#_ O@WQS%=6EEX>L[A=*LK/P#IE_X?M+6\MY;+4+W
M4?M5S?6;6MI:8%G^PK\'K3X=?!#X9Q^+_B.=$^ S_M'/X4NVU3PX=4U(_M->
M%/BAX0\;_P!O2+X:%K<?V/IWQ7U^?PQ]AM=/^RWMEI,FI_VK##=P7GI__"W_
M  Q_S\WO_@,W_P 71_PM_P ,?\_-[_X#-_\ %T_JF46MSX:S;?Q]6XR;>KW<
M(MV[>MTLTXJYE)X?,;I12?L-E"-2$5MM&-6I%>4WOHX_/6C?\$_?^$-^(VG?
M$SX7?MA_M,_#?6]&^"7PC_9ZT6WTVP_9Y\66OA_X5?"#PWHVBZ=X5\,W'Q(^
M!/C/5/"^F^+]9TEO'?C^T\/:AIL'BGQI>+J=[']ET7PS8Z)ZGX1_8\T3P'\0
M(M;\%_M!_M#>%?A%#\6=:^.47[-F@^)?!FF_"N/XC^)/%.H^.?$*QZ]:^ T^
M,2_#G6_'&KZKXRU/X2?\+._X5]>:]J-Y!-HC>&9W\-'M!\8?# _Y>;[_ ,!V
MQ^18T\?&3PP/^7B]_&V)_P#9JCZCE$6G&IA])<ZM6J:2]V[_ (B24N6/-%>[
M+ECS1?+&VKSGBF2:GA<=*\%3;>#I7<%S\MVJ*;E'VE3DFW[2G[2IR3BZDW+
M;]C7X-W'[)VJ_LA7NL>.;CP3<^+O'?Q$\.^.(M8T_3_B?X ^(_C#XS>)_CWH
MWQ!\"^)=.T:TM=!\6_#?XD>)O[8\!ZE'I,XLX]'TVTUF'6[>35(]1S=3_8L^
M'_B'XL6W[0_B/XH_%C6/VCM'\<?#SQ-X2^-+:KX;T_Q#X(\(> =#G\.W?P2\
M*Z'IWANT\):?\%_B/IVM^.+GXI>#I-"N)/&/B'QYJWBBXU.WU_P_X OO!W8_
M\+D\,?\ />\_\!3_ /%4X?&?PT.ES>_^ I_^*S2>"RE\O[S#>ZHJ/[RUN2_)
M:SWA=\DG>4;OEDKL<<WXGCSOZMF-ZDJDY_N&W)U5%5;MQ=HU5"*J07+"IRQY
MX2LCV?X\?#GP%^T=\,-=^$_Q'76!H.LW6@ZQ8:QX9UR]\,>,?!_B[PAKVF^+
M/!'COP3XHTQH]0\-^,_!/BW1='\3>&=9M'8V>K:9;&X@N[)[FSN/F71/V)?!
M.M^(=7\4_M(_&GXT_M>:O=_"CXC? WP[%\;;[X>:7H/@CX8_%W2K70?BAIOA
MOPU\'/A]\+=%;Q3\0- LK/0?%/C_ %BTU/Q=<Z+:KI6EZGH]C=:E!?\ ;#XT
M^&AUGO#_ -NS#_V:G?\ "Z_#7_/>]_[\/_\ %TIX/+)R4IUL/)JRNZETTKVY
MHW49\O-+EYXRY>9\MKE4LVXCHP=.E@\PA!MNT:#O%RY.=PFXNI3Y^2'/[*I3
M4U"/.I61XO-_P3L\!^)?!WCWPA\5OVC/VE/C4/$O[.WC?]E7P-KOQ&\2_#Z?
M6O@Y\%?B(?#;>+],\%'PS\-_#FGZUXT\2'P;X.C\0_$CXC6'C;QEK-IX4T2S
MNM3$ U1=59\9OV5OBA\8/VV=5^,>A_&[XL_ /X?S?L=>#_@._C+X*^*? UCX
MO\2:DGQ<^(WB?Q?X4U71?'/@;QS:Z?!%X;US0+_POX_T2RTGQ3X7UJ?43X=U
MBS>:_CN/;1\;?#0_Y;WI^MJQ_P#:@S^-2?\ "\/#/_/:]_\  8__ !592R[*
MVE%5J"2E&3Y:S3DX<S2E)R<VO>>TD[)+FY58ZH9]Q)&4IRP>,FW3J4US82+C
M!5%34I0I^S5-2M36]*4;N<G%SDY'E/BS_@G9\']1LKCPU\+_ (K?'+]GOX=>
M*?@C\//V<?BU\-_A#XF\*0>'?B[\'OA9X<O_  9X+T#Q%J7C?P7XT\6^&=?L
M/!.J7_@F]\??#OQ'X/\ &VK^%ITL=2URXO-/T?4M,[_QA^PS\!_&?P__ &HO
MAE+J'C'0?!_[4]S\(+OQ%IGAW4-"LX/ <OP,^'_PR^'WPYM_ 5M?>'M1T_\
MLK2['X2^$=0U#0?&-EXMT+79X]2TG6].O_#.I7.AML_\+Q\,_P#/6]_\!L_U
MIX^.?A@?\MK_ /\  ;!_1_Z4GEV5ZOVF%U337M-+.+BTE?EBFF[J*BFW=KF]
MX:SWB3W;X;,O=<9)N@W+FA.-2,I2Y%*<HRC%QE4E.224$^2\'XHO_!-WP#?:
M1\<E\2?M$?'_ ,3^-?CWX>_9VTKQ)X_NC\&=#O\ PGK'[*WQ2U#XP?!37_AQ
MX/\ "'PA\/?#7PC!X;\8WXFU#PK!X-NO"OB"WBEDU;2KC5=3U?5-0[O6/V$?
M -SJFI^.O"?QG^,_PX^-T_QX\9?M"Z'\;O"%Y\/G\6>&_%OQ)^%?@/X1?$GP
MU;^'O$O@#Q!\/-;^'GCKP[\//#^I:UX2\3^#]:B@\26MGK>C7FEW.CZ+_9W:
M?\+W\,?\]+[_ ,!S_P#%TX?'GPR/^6M]_P" [?TD%1_9N6+_ )>8?K;]ZVU=
MMWOSWYKMOFOS)O1K8U6?\1/5X;,.EU]5CRM**@H\OL^5PY8J+@XN#25XO=W?
M@U^Q]\)_@GXO^$7CKPYXK^(VO>*_A7HW[25M>:_XPUS1]8UGXG^+/VKO'7P[
M^(OQA^)'Q(O;?0=-.H>,=5\3_#;1YM+'A^/PYX:T33;JZT73?#UOI%IHUEI?
MK_[/_P &_A[^SU\"/ G[/7A^34/%W@?X?VFH6NE3>/$TC6=4O!J/B#5O$<DV
MI?9M,T_2IIX+W6+F.W>WTRW$=ND((:4/*_BH^/?AD?\ +2^_"!OU^<YJ0?'[
MPR.KW_U$'_V0H6 R^'P5L.K)I6FFK/EOO??DC>^]K[MMDLZSNII4PF82NXR=
MZ$UK%U'%^ZHVY?:U.5*R2E9))14?LK2#X4T*X>ZT/P]X?T6ZEA-O)<Z3I&G:
M=<20,Z2- \MG;Q2/"9(HY&C9RA>-'*ED4CS+Q#\+/"'B;]HGX5_M+7NL>((?
M&OPD^%_Q<^%'A_2+:ZT\>&K[0?C+KWPM\0>)+[5[:339M3EU:PN_A+H$6C2V
M6JV5I#;WVK+>V=])+9R67@H_: \,#^/4/_ ?_%C3Q^T'X9'1]0]OW'3]:)8'
M!2LO;8?1J2]^*M*+NGHEJGK_ )CAF^;0;:P6/3E&4)/ZO4;<)QY91;;D[2CH
M_+9HV)/V/?A1-H/C?P^WBGQV+3QY^VKX(_;HU64:AH7VBV^*7@3Q_P##/XB:
M5X;L&;P\43P)<ZQ\+-!M+^PGCN-<DTZ\U6.#7K>XEM;FTN?"G]D3X4?"3XA^
M$OB/HGB+QIJVJ^$+3]L*QLM-U^\T*[T6^M_VU/V@O#_[1OQ.34[:VT"SGG70
MO&'ARTT;P:L=S"MKX8GN[/6UUW4'BU*+GA^T-X9[MJ!_[8D?^S4\?M$>&!U-
M_P#]^,_^S#]:R>78&Z?M,/=6L_:*ZLVUUZ.3>W5G0L^SGEE%X;'\LDU*+P\[
M-.,8M:13UC"*T:V6V[Y'X2?\$^?A[\(_B;\ /'>F_'S]HGQ3X1_91G\?6W[-
MGP5\8>)_ VH?#+X3>%/B'X"USX>:CX,L&L/A]I7COQ5I'ASP_K8TOP'?^.O&
MOB;Q!X0T#2=,\-:?J[:0VJ0ZG[/^T7^R_P"$_C[XL\-_%+0OBA\3_@'\:_"O
M@[Q)\-[+XM?!V_\ "<>N:Y\,/%]U::AX@^&GCOPYX\\*^-_ _CCP7<:M86FO
M:79Z]X:GU7PMK\4NK^$M8T*ZU'6#J7%#]HOPR.^H?]^/Z[SQ4@_:.\,>FH?]
M^!_4FI66X)1E!5<.HR:DU[5;I)1:?-S1Y4DHV:Y4DDDM'K_K!F\IQJRPV.=2
M$7!2^JR^&3<I)Q]GR24Y2E*?/&;G)N4FY/F7A?PZ_P""7'P[^'_PE^)_PA_X
M:,_:!\6#QQ\4_@?\=O"GQE\8ZKX+\0_M&?#SXR_ 2/PO'X$\4P_%+4_"=Y9>
M.- \/Q^!/!FF^%/ ?CKP?K7AKPMX;T_5_#%K!=Z1KKP671ZC_P $T/ &JV%_
MJEW^T7\?M2^+MY^TG9?M6Q_&KQ-#\$O&OB6'XLI\ ],_9NU627P-XM^#FL_!
MR^\+ZA\-+"2UTGP[??#B:+P/J<UO>^!;CPZNF6$$7J8_:1\,=QJ)_P"V6#_/
M^E2+^TGX7';4?IY(Q_,9_&LWE6!M93P^BLOWVRNWUGNKNS=Y+92L;_ZR9Q=M
MT<<W*7-)_59*[LD]%12LU%<T5:$FKN%]3)^!_P#P3[^$'P,\:_#OQ[HOQ)^,
MGC'Q#\./C/\ M#_':QU'Q_K_ (4U:]\0^.OVG/!6D^$/B=-XHNM)\%Z#]ML9
M)].N?$>A6NFPZ2ND:GJMQ81%_#]IIFD66-=?\$[O!%I?3>(? G[0GQZ^&_CC
M0?CM\=_CM\(?''AN7X4:AJ_P?N_VGM8N?$_Q\^&>D:;XL^%WB'PQXY^$WQ&\
M87?_  E=WX:^*6A>--5T/6--\/S>'/$.D_V!IWE=F/VEO"PZIJ.?40C_ .*&
M/UIX_:8\*C^#4O\ ORO]6-2\KP=DE/#V3NK54K-I*Z?/>_NKKHTFK/4:XBS5
MR<G1Q]VDFWA).Z3E*S3IN-KRE=<MFI.+3C[J[OX8_LK>$?AWX^^#GQ1OOBI\
M8_B=X_\ @]X"^/G@:+Q7\4?%6D>(M7\;?\-&>./AKX_\=:[XKDM/#NDVMG<Z
M9J_PNT#3O!'A[P59^$O _@_PY-=:!I'A:'3X=-CL.<_:M_8_M_VIOB7\$/BB
M?VC/C3\'M;_9_G\0ZQ\/M'^'VG?!;Q+X0@\:^(8K:S'Q'U#PI\9?A/\ %#0[
MKX@^'-)@N-(\%>*A9Q:EX,L]8\02>')=.OM;U"\FRE_:;\++_!J7_?H=/;YL
M#\JF'[3_ (5'_+/5/PC _P#9N:3RS#-./M*/*VFU[:VJM9W4KW7+'6^ME>Y<
M>(,Q4U4^KXWG4913>$E)*,N;FBHNERI/GFK<EDI-*RT*GCW]B.;QU<^!_%\?
M[7O[3O@GXW>'OA=KWP0\=?'WP'>?!;0?B'\8OA+K_B:?Q7_PB_CC2I/@]??#
MC2]5\+:M=WMQX \:^ ? W@_Q=X+FU/6KC2]6,NMZH;KV3Q%^RW\'=9^"OP#_
M &?]$CUOP5\,_P!F_P <?LY>-OAGI'AF_@:XM#^S#XM\*>+_ (>>']3O=;M-
M8N-2T>[NO!^F6'B2:1UUO5+*6]F35[;4K@WR^4_\-1>%?^>6IG_MD/Z,*<O[
M4GA5?^66I_\ ?L?_ !1-+^S,-[UIT?>5F_:Q=[-/K)VNXQ;>CDTG)MJY7^L&
M/?+>AC;0;E!+"3BHMJ2Z4EHE.<8IWC",I*"@G8T?CA^Q/X6^//COQAK/BCX_
M?M&:5\(_BP?!A^./[,VB^.-!D^"?Q97P+!86-A8WUMKOA+6_'?P_T/Q5I&EZ
M9H'Q3\.?"3QQX"T+XH:)81VGBVPO9[[7+O5_>_VC?@;\.OVG_AU;_#WQ[=>)
MM!;1/%GA?XA> O'GP_UO_A%_B+\+_B3X(U :IX/^(7P^\1&SOXM'\3:#=>=%
M&;W3M4T;5M)OM5\/>(='UGP[K&JZ3>_/ _:H\*#_ )8:G]?*3] ?\:>/VJO"
M?>#5#_VR0?UI?V;1M)<]!\_Q?OHN^M^LG97;:4>5)NZ2>I?]OXR]-^QQB=+^
M'_LM5<KLE?W::YG9*+<^=N*46W'W7DZ=_P $]_AIXF;XLZG^TO\ &+XV_M<>
M+?BY\#_%7[-E_P"*/C!J_@CPX?!7P3\;W5IJ'C#PC\-O#/P5\#?"SPAX0U+Q
M7JVD^&];\2^.;?0KGQWJFK>$O"LH\16UGH.G6,'*ZM_P3,^'WCWP[\2['XW_
M +2'[2OQ[\8?$'X;>%/@OIGQ-^).N_#.'Q=\//A'X2^)'AKXJIX1\(6?@CX8
M>#O"$U_XM\7^$/#.H?$/QMXG\,>(?&?C)M T9;[6X8M+LXHO0Q^U9X3'_+OJ
MGXQK_+-2#]K#PGWMM5_[X7G_ ,>%9/*J&GO47O>]6.M[WYFYWD]79R<FK^ZT
M;1XCQJO^[QBOR[8.:4>6UE!*DE!:)-048R22FI'6?%7]BWX4?%[QI\8?'/B#
MQ1X]T_5/C3<_L:77B2WT74= ALM.D_8C^-6N?'/X9#1$O- O)X%\1^*=>NM-
M\<?;9[YK[0H;>#1&T&^62_DY:V_83\.Z'\5/$7C+P/\ M(?M)?#KX7>-?C3)
M^T-XX_9R\%^)_ VE_#+Q+\6;_P 0V/B_Q/J2^*9?A_=?&WP[X0\?^+[$^*OB
M)\.?"OQ6T7P9XNUG4=<6^TI-(\0Z]I&I*/VL_"(X^RZK^"+_ /%\_G3Q^UIX
M0'_+KJQ_[9I_5S0\LHMWYJ*=[W56.^M]IK>[NMGU3TLX\0XI+E]EB^7EY;/"
M59*R22LG2:322Y9*TH[QDFVW-K'[!'PHU'X1:)\,=%^(GQ5\%^(?!'[2OQ7_
M &LOA9\8O"NK>%+?XE?#+XQ?%_X@_%+Q[XGO-!75?".K^"=8\+2V_P 8_'?@
M*Y\'^,?!WB/1-:\ :Q-I&NV^HZDL6LQ[W@?]C'P]X>\2_!/Q[XV^._QX^,WQ
M%^"_QA^(GQNL_&?Q+U[PA/+XC\5_$CX)>(_@+J6AS>&O"O@KPQX-\&> -"\&
M>([BY\,>"?AIX=\&:59>(;?^W=1_M;4]4\076L<^/VN/" &/L>J_A'&/ZFI%
M_:Z\'#_ERU;/KLB/^&*G^S*:ZT=+)6JP2M%WCISV;6EFTW;2]M"_]8<0TTZ>
M+LW)O_9*MWSJTO>]DY)23UC&2BWK:^IB:E_P3Q\$64NE>)?A3\?/CS\#OBOH
M/Q._:C^(>C?%SX?ZA\-K[Q)'I'[8/Q43XP?&;X7:OX=\>_#;QEX \1_#RZ\9
M6/A[5?"]KK?A*\\2>%M2\)>'=5T[Q&+Z+5I-7Y^;_@F?X,T.59O@Y^U+^UI\
M#KKQ)\,O!OPH^->M^#OB!X+\5>,/CSHW@:'7;;1/&?CCQQ\6?AW\0O%GA_XQ
M"S\2ZWILWQ8^&>K>!O%2Z5<V.FVT]M;>'/"BZ#WO_#7G@[_GSU<_\ C_ *$4
M\?M?>#1_RX:L3Z[8_P#&I>5T^CH_^#HKOJK559M-IM6;6C;6BTCQ'7ZPQ771
MX2K*ZT=G?#M22:3BI<T8R]Z*C)MOZU\:?##X<?$CX0^)/@1\0-"C\8_"WQCX
M U#X8>*O#?B/4=4U23Q#X,U;0I/#FI:=JNM7-\^O75Y>Z5+(DVN/JG]N&\;^
MTUU%=2"W8^.O ?\ P3^TG1O'/PC\5?%K]J?]J']IKPW^SQKL?BOX#?#7XX>)
MOAK?^$_ OC&TT'4_#.B>.?$6H^"/AAX)\:?%WQOX3T+6=5L/"'B7XM^*O&-W
MHL^H7.OLEYXM%MXAMM1?VP?!HZV.K_0+'C\?FYI__#8G@S_GPU?_ +YC_P#B
MJ<LMC)IN5*ZM;][#HTTFE-)I-)I24DFKI)BAG\X*48T\6E)MM+"UMVG%M-T6
MXR<6XN4'!N+:;:T7B?P?_P""2?P=^#OB;X(:OI?QV^/WB'PW^S9>?%%?@?\
M#G69O@YIOA#PCH'Q<^&GC;X6^*=+UZ;P;\(?"WBSXG:XGA[QQ>/IWQ"^*'B?
MQ?\ $"WN-,LO.\17$>H^*5\1>Q?#S]ART_9\T&R3]G7XK>-?#GC"W^#O["/[
M.3^(?%S^$M:@;X-_L5^)=;189;(^"9K>?Q-\3/A[XV\<>&O&%U%;6<4]U>:5
M<^%IO MU;-JT5U?VQ?!0ZZ?K/X"(?GR*D'[9'@H?\P[6?^^8?ZDUFLKC';V*
M[-5H76EM+U+JR5EV6B-GQ%4G\<<5*^ZEA*SB]7)W2H).\FY.^[U;;/H#XD?
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M;0QP6UK:V\:PV]O;P1*L<,$$2)%%%&JI'&JHBA0 )_(BZAC^H'Z5\.?\-O\
MP_\ ^@-KW_DO_C2C]M_X?=]%UX_C;C^M4L%7_P"G:_[BTO\ Y,R_M7!]56_\
M(\6_SI,^X?LT?^S^?_UJ3[*GJG^?QKXA'[<'P\_Z FO_ /DN?YM2_P##</P\
M_P"@)KWY6W_Q5'U3$?W/_!U+_P"6!_:F"?2O\\+B_P!*!]N?94_O+^E--DIY
MQG\O\:^)O^&XOAZ.FBZ^/_ ;_P"*I?\ AN/X>?\ 0$\0?G;?XT?5,0OY/_!U
M+_Y,?]IX'M6^6$Q7ZT?T/M?[$/[H_,?X4&R'95_$Y_PKXI_X;D^'G_0#U_\
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(W*2T7>R?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
